Linaclotide vs hBD-1
Head-to-head comparison of Linaclotide (Linaclotide) and hBD-1 (Human beta-defensin 1) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Linaclotide | hBD-1 |
|---|---|---|
| Category | Gastrointestinal | Dental & Oral |
| Full Name | Linaclotide | Human beta-defensin 1 |
| Molecular Weight | 1526.8 Da | 4490 Da |
| Half-Life | Active locally; negligible systemic half-life | minutes to hours |
| Amino Acids | 14 | 36 |
| Typical Dose | 72-290 mcg once daily | 1-10 µg/mL in experimental studies |
| Route | Oral | Topical/Intraoral |
| Purity | ≥98% | ≥98% |
| Studies Count | 1200 | 85 |
| Research Status | Clinical | Pre-clinical |
Linaclotide Benefits
- ✓improves-bowel-movements
- ✓reduces-abdominal-pain
- ✓increases-intestinal-secretion
- ✓supports-transit
hBD-1 Benefits
- ✓oral innate immunity
- ✓broad antimicrobial activity
- ✓biofilm suppression
- ✓periodontal support
Linaclotide Dosing
72 mcg PO daily|145 mcg PO daily|290 mcg PO daily
hBD-1 Dosing
topical peptide exposure|cell-culture or mucosal models|repeat low-dose application in research
Linaclotide Side Effects
- ⚠diarrhea
- ⚠abdominal-pain
- ⚠bloating
hBD-1 Side Effects
- ⚠protease degradation
- ⚠local irritation at high dose
- ⚠limited stability in saliva
Research Overview
Linaclotide
Linaclotide has extensive clinical evidence for chronic idiopathic constipation and IBS-C, with consistent effects on stool frequency and abdominal symptom relief. Its mechanism is local GC-C activation in the gut with minimal systemic exposure.
hBD-1
hBD-1 has been studied as part of the oral mucosal defense system and is linked to host resistance against dental pathogens. Research spans periodontitis, candidiasis, and epithelial barrier biology.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.